PRINCETON, N.J., March 1 /PRNewswire-FirstCall/ -- Pharmacopeia , an innovator in the discovery and development of novel small molecule therapeutics, today announced that David M. Floyd, Ph.D., the Company’s Executive Vice President and Chief Scientific Officer, will present highlights of Pharmacopeia’s DARA program at the R. Bryan Miller Memorial Symposium. The symposium will be held at the University of California, Davis on Friday, March 9, 2007.
Dr. Floyd’s presentation entitled, “Dual Acting Receptor Antagonists,” will take place at 1:15 pm PST and will provide an overview of the discovery and design of Pharmacopeia’s lead DARA compound, PS433540, for which the Company has recently initiated Phase 1 clinical trials.
PS433540 is a Dual-Acting angiotensin and endothelin Receptor Antagonist (DARA) that combines the properties of two marketed product classes, namely an angiotensin receptor blocker (ARB) and an endothelin receptor antagonist (ERA), in the same molecule. PS433540, the first and only DARA compound in development, is being developed as a potential treatment for hypertension and diabetic nephropathy. PS433540 is highly selective for both the angiotensin II receptor sub-type 1 and the endothelin receptor sub-type A. There is considerable preclinical data suggesting that, compared to either agent alone, simultaneously blocking the actions of both angiotensin II and endothelin 1 may provide significantly improved treatment options for several cardiovascular diseases. In addition in preclinical studies, PS433540 has demonstrated an excellent pharmacodynamic, pharmacokinetic and safety profile.
ABOUT PHARMACOPEIA
Pharmacopeia is committed to discovering and developing novel therapeutics to address significant medical needs. The Company has a broad portfolio advancing towards clinical validation, both independently and with partners. Pharmacopeia’s most advanced internal program is a Dual-Acting angiotensin and endothelin Receptor Antagonist (DARA) for hypertension and diabetic kidney disease for which Phase 1 clinical trials are underway. Other internal proprietary programs address primarily immunoregulation. Four partnered programs are in active clinical trials: a CXCR2 antagonist in Phase 2 for chronic obstructive pulmonary disease (COPD), p38 MAP kinase inhibitors for rheumatoid arthritis, an enzyme inhibitor for oncology and a candidate for metabolic diseases. Four additional partnered compounds are in preclinical development. Pharmacopeia’s current strategic partnerships are with Cephalon, GlaxoSmithKline, Organon and Wyeth.
Contact: Amy P. Sharpless Pharmacopeia (609) 452-3643 ir_pr@pcop.com
This press release, and oral statements made with respect to information contained in this press release, constitute forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements include those which express plan, anticipation, intent, goal, contingency or future development and/or otherwise are not statements of historical fact. These statements are based upon management’s current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. These forward- looking statements include, but are not limited to, statements about the successful implementation of Pharmacopeia’s strategic plans, Pharmacopeia’s plans to develop PS433540, a compound from its DARA program, Pharmacopeia’s Phase 1 clinical studies with respect to PS433540, Pharmacopeia’s ability to successfully perform under its collaborations with Cephalon, GlaxoSmithKline, Organon and Wyeth, Pharmacopeia’s ability to build its pipeline of novel drug candidates through its own internally-funded drug discovery programs, third party collaborations and in-licensing, Pharmacopeia’s ability to raise additional capital, Pharmacopeia’s expectations concerning the development priorities of its collaborators, their ability to successfully develop compounds and its receipt of milestones and royalties from the collaborations, Pharmacopeia’s anticipated operating results, financial condition, liquidity and capital resources, Pharmacopeia’s expectations concerning the legal protections afforded by U.S. and international patent law, Pharmacopeia’s ability to pursue the development of new compounds and other business matters without infringing the patent rights of others, additional competition, and changes in economic conditions.
Further information about these and other relevant risks and uncertainties may be found in Pharmacopeia’s Reports on Form 8-K, 10-Q and 10-K filed with the U.S. Securities and Exchange Commission. Pharmacopeia urges you to carefully review and consider the disclosures found in its filings which are available in the SEC EDGAR database at http://www.sec.gov and from Pharmacopeia at http://www.pharmacopeia.com. All forward-looking statements in this press release and oral statements made with respect to information contained in this press release are qualified entirely by the cautionary statements included in this press release and such filings. These risks and uncertainties could cause actual results to differ materially from results expressed or implied by such forward-looking statements. These forward-looking statements speak only as of the date of this press release. Pharmacopeia undertakes no obligation to (and expressly disclaims any such obligation to) publicly update or revise the statements made herein or the risk factors that may relate thereto whether as a result of new information, future events, or otherwise.
Pharmacopeia Drug Discovery, Inc.
CONTACT: Amy P. Sharpless of Pharmacopeia, +1-609-452-3643, orir_pr@pcop.com
Web site: http://www.pharmacopeia.com/
